|
| Wednesday, 30 March 2016, 17:05 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
TOKYO, Mar 30, 2016 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that based on recent trends in business results, etc., the company has revised its full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016) previously announced on February 2, 2016, as follows:
1. Revised full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016)
2. Reason for revision of the consolidated financial results forecasts
- Revenue is forecasted to be Yen547,000 million (down 0.3% from the previous fiscal year) due to the impact of the latest results of the Japan pharmaceutical business and exchange rates.
- Operating profit is forecasted to be Yen51,000 million which is unchanged from the previous forecast as the impact from the decrease in revenue will be offset by further progress in cost optimization.
- Profit for the period is forecasted to be Yen50,000 million (up Yen13,000 million from the previous forecast), attributable to the transfer of shares in AkaRx Inc. by Eisai's U.S. subsidiary Eisai Inc. as announced today.
Furthermore, Eisai intends to set the dividend for the period (second six-month period ending March 31, 2016) at Yen80 per share, with the forecast for the total dividend for the year remaining unchanged at Yen150 per share (same amount as the previous fiscal year).
Please note that actual business results may change due to several factors since the above-mentioned forecasts were made based on information available as of March 30, 2016.
Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: Daily News
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
